Abstract
Background Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant neurological disorder caused by mutations in the NOTCH3 gene. Disease-causing variants in NOTCH3 are primarily missense variants altering the number of cysteine residues in the translated NOTCH3 protein. The genetic screening of the NOTCH3 gene is currently considered the gold standard for CADASIL diagnosis. Methods The Genomics Research Centre has been performing diagnostic genetic testing for CADASIL since 1997. A total of 1281 patient samples suspected of having CADASIL were screened for NOTCH3 mutations from January 1, 1997, to October 1, 2025. Genomic sequencing was performed using Sanger sequencing of selected NOTCH3 exons or using next-generation sequencing to screen the entire NOTCH3 gene. Results In total, 12.1% of patients had a cysteine-altering NOTCH3 variant, including 49 variants in exons 2-24, and two variants in non-EGFr encoding exons. We also report the first CADASIL patient who is a compound heterozygote for two known pathogenic cysteine-altering NOTCH3 variants, who presented with a severe early onset of stroke, migraine, and white matter changes. Conclusions The compound heterozygosity identified in this patient appears to be associated with an early onset of CADASIL symptoms. Our study contributes to the elucidation of the spectrum of NOTCH3 variants associated with CADASIL. The majority of patients tested for CADASIL in this study did not contain a variant in NOTCH3, indicating that there are other genes or genetic variants contributing to disease in these patients.